Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2′-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. (1st July 2021)
- Record Type:
- Journal Article
- Title:
- Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2′-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives. (1st July 2021)
- Main Title:
- Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2′-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives
- Authors:
- Bai, Bingfang
Bi, Fangchao
Qin, Yinhui
Teng, Yuetai
Ma, Shutao - Abstract:
- Graphical abstract: Highlights: Novel 3- O -descladinosyl-3-keto-clarithromycin derivatives were synthesized and evaluated. Some of them showed effective activity against resistant strains. Compound 9b exhibited prominent antibacterial activity. Abstract: A novel series of 3- O -descladinosyl-3-keto-clarithromycin derivatives, including 11- O -carbamoyl-3- O -descladinosyl-3-keto-clarithromycin derivatives and 2′, 9(S)-diaryl-3- O -descladinosyl-3-keto-clarithromycin derivatives, were designed, synthesized and evaluated for their in vitro antibacterial activity. Among them, some derivatives were found to have activity against resistant bacteria strains. In particular, compound 9b showed not only the most significantly improved activity (16 µg/mL) against S. aureus ATCC43300 and S. aureus ATCC31007, which was >16-fold more active than that of CAM and AZM, but also the best activity against S. pneumoniae B1 and S. pyogenes R1, with MIC values of 32 and 32 µg/mL. In addition, compounds 9a, 9c, 9d and 9g exhibited the most effective activity against S. pneumoniae AB11 with MIC values of 32 or 64 µg/mL as well. Unfortunately, 2′, 9(S)-diaryl-3- O -descladinosyl-3-keto-clarithromycin derivatives failed to exhibit better antibacterial activity than references. It can be seen that the combined modification of the C-3 and C-11 positions of clarithromycin is beneficial to improve activity against resistant bacteria, while the single modification of the C-2′' position is veryGraphical abstract: Highlights: Novel 3- O -descladinosyl-3-keto-clarithromycin derivatives were synthesized and evaluated. Some of them showed effective activity against resistant strains. Compound 9b exhibited prominent antibacterial activity. Abstract: A novel series of 3- O -descladinosyl-3-keto-clarithromycin derivatives, including 11- O -carbamoyl-3- O -descladinosyl-3-keto-clarithromycin derivatives and 2′, 9(S)-diaryl-3- O -descladinosyl-3-keto-clarithromycin derivatives, were designed, synthesized and evaluated for their in vitro antibacterial activity. Among them, some derivatives were found to have activity against resistant bacteria strains. In particular, compound 9b showed not only the most significantly improved activity (16 µg/mL) against S. aureus ATCC43300 and S. aureus ATCC31007, which was >16-fold more active than that of CAM and AZM, but also the best activity against S. pneumoniae B1 and S. pyogenes R1, with MIC values of 32 and 32 µg/mL. In addition, compounds 9a, 9c, 9d and 9g exhibited the most effective activity against S. pneumoniae AB11 with MIC values of 32 or 64 µg/mL as well. Unfortunately, 2′, 9(S)-diaryl-3- O -descladinosyl-3-keto-clarithromycin derivatives failed to exhibit better antibacterial activity than references. It can be seen that the combined modification of the C-3 and C-11 positions of clarithromycin is beneficial to improve activity against resistant bacteria, while the single modification of the C-2′' position is very detrimental to antibacterial activity. … (more)
- Is Part Of:
- Bioorganic & medicinal chemistry letters. Volume 43(2021)
- Journal:
- Bioorganic & medicinal chemistry letters
- Issue:
- Volume 43(2021)
- Issue Display:
- Volume 43, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 43
- Issue:
- 2021
- Issue Sort Value:
- 2021-0043-2021-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-07-01
- Subjects:
- Antibacterial activity -- Bacterial resistance -- Synthesis -- 3-O-descladinosyl-3-keto-clarithromycin derivatives
Bioorganic chemistry -- Periodicals
Pharmaceutical chemistry -- Periodicals
572 - Journal URLs:
- http://www.elsevier.com/wps/find/journaldescription.cws_home/972/description#description ↗
http://www.sciencedirect.com/science/journal/0960894X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.bmcl.2021.128110 ↗
- Languages:
- English
- ISSNs:
- 0960-894X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2089.330000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17218.xml